Repligen Corporation (RGEN)
Market Cap | 9.35B |
Revenue (ttm) | 801.54M |
Net Income (ttm) | 185.96M |
Shares Out | 55.56M |
EPS (ttm) | 3.24 |
PE Ratio | 51.96 |
Forward PE | 56.50 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 543,926 |
Open | 171.25 |
Previous Close | 169.57 |
Day's Range | 167.73 - 173.84 |
52-Week Range | 137.21 - 262.26 |
Beta | 1.09 |
Analysts | Buy |
Price Target | 207.26 (+23.11%) |
Earnings Date | Apr 26, 2023 |
About RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput... [Read more]
Financial Performance
In 2022, Repligen's revenue was $801.54 million, an increase of 19.54% compared to the previous year's $670.53 million. Earnings were $185.96 million, an increase of 44.95%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price forecast is $207.26, which is an increase of 23.11% from the latest price.
News

Why Is Repligen (RGEN) Down 11.4% Since Last Earnings Report?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virt...

Repligen's (RGEN) Q4 Earnings and Revenues Beat Estimates
Repligen (RGEN) reports encouraging fourth-quarter and full-year 2022 results, with sales and earnings beating estimates.

Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates
Repligen (RGEN) delivered earnings and revenue surprises of 17.24% and 0.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Repligen Reports Fourth Quarter and Full Year 2022 Financial Results
WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f...

Repligen Appoints Martin D. Madaus to Board of Directors
WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus.

Repligen to Report Fourth Quarter and Full Year 2022 Financial Results
Webcast and Conference Call to Be Held Wednesday, February 22, 2023 at 8:30 a.m. EST Webcast and Conference Call to Be Held Wednesday, February 22, 2023 at 8:30 a.m. EST

HZNP vs. RGEN: Which Stock Is the Better Value Option?
HZNP vs. RGEN: Which Stock Is the Better Value Option?

Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at th...

Repligen (RGEN) Up 4.3% Since Last Earnings Report: Can It Continue?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

BIIB or RGEN: Which Is the Better Value Stock Right Now?
BIIB vs. RGEN: Which Stock Is the Better Value Option?

Is Repligen a Value Trap or a Value Opportunity?
The past 14 months have disappointed many shareholders of Repligen Corp. ( RGEN , Financial). Its price fell from $324.21 on Sept.

Frank Sands Is Loading Up on This Underestimated Biopharma Stock
Sands Capital Management recently disclosed its 13F portfolio updates for the third quarter of 2022, which ended on Sept. 30.

Repligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at tw...

BIIB vs. RGEN: Which Stock Is the Better Value Option?
BIIB vs. RGEN: Which Stock Is the Better Value Option?

Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance
Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022

Repligen (RGEN) Q3 Earnings and Revenues Top Estimates
Repligen (RGEN) delivered earnings and revenue surprises of 13.24% and 4.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its t...

Repligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands
WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement with Purolite, An Ecolab Company (“Purolite”), ...

Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?
Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

LGND vs. RGEN: Which Stock Is the Better Value Option?
LGND vs. RGEN: Which Stock Is the Better Value Option?

Repligen (RGEN) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Repligen to Report Third Quarter 2022 Financial Results
Webcast and Conference Call to Be Held Tuesday, November 1, 2022 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Tuesday, November 1, 2022 at 8:30 a.m. EDT

4 under-the-radar stock picks from a five-star fund manager who sees rewards that are worth the risks
It can be tempting to chase performance during any given year, but unfortunately it's a tried-and-true way to lower your investment returns in the long run.

REGN vs. RGEN: Which Stock Is the Better Value Option?
REGN vs. RGEN: Which Stock Is the Better Value Option?